Your browser doesn't support javascript.
Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge.
Lorent, Natalie; Vande Weygaerde, Yannick; Claeys, Eveline; Guler Caamano Fajardo, Ipek; De Vos, Nicolas; De Wever, Walter; Salhi, Bihiyga; Gyselinck, Iwein; Bosteels, Cedric; Lambrecht, Bart N; Everaerts, Stephanie; Verschraegen, Sven; Schepers, Christophe; Demeyer, Heleen; Heyns, Arne; Depuydt, Pieter; Oeyen, Sandra; Van Bleyenbergh, Pascal; Godinas, Laurent; Dupont, Lieven; Hermans, Greet; Derom, Eric; Gosselink, Rik; Janssens, Wim; Van Braeckel, Eva.
  • Lorent N; Dept of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Vande Weygaerde Y; These authors contributed equally.
  • Claeys E; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Guler Caamano Fajardo I; These authors contributed equally.
  • De Vos N; Dept of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
  • De Wever W; These authors contributed equally.
  • Salhi B; Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU Leuven, Leuven, Belgium.
  • Gyselinck I; Dept of Radiology, Ghent University Hospital, Ghent, Belgium.
  • Bosteels C; Dept of Radiology, University Hospitals Leuven, Leuven, Belgium.
  • Lambrecht BN; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Everaerts S; Dept of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Verschraegen S; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Schepers C; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Demeyer H; Department of Intensive Care, Ghent University Hospital, Ghent, Belgium.
  • Heyns A; Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
  • Depuydt P; Laboratory of Immunoregulation, VIB-UGent Center for Inflammation Research, Flemish institute for Biotechnology, Ghent, Belgium.
  • Oeyen S; Dept of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Van Bleyenbergh P; Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Godinas L; Dept of Radiology, University Hospitals Leuven, Leuven, Belgium.
  • Dupont L; Dept of Rehabilitation Sciences, KU Leuven, Leuven, Belgium.
  • Hermans G; Dept of Rehabilitation Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
  • Derom E; Dept of Physical Medicine and Rehabilitation, University Hospitals Leuven, Leuven, Belgium.
  • Gosselink R; Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
  • Janssens W; Laboratory of Immunoregulation, VIB-UGent Center for Inflammation Research, Flemish institute for Biotechnology, Ghent, Belgium.
  • Van Braeckel E; Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
ERJ Open Res ; 8(2)2022 Apr.
Article in English | MEDLINE | ID: covidwho-1854769
ABSTRACT

Background:

Long-term outcome data of coronavirus disease 2019 (COVID-19) survivors are needed to understand their recovery trajectory and additional care needs.

Methods:

A prospective observational multicentre cohort study was carried out of adults hospitalised with COVID-19 from March through May 2020. Workup at 3 and 12 months following admission consisted of clinical review, pulmonary function testing, 6-min walk distance (6MWD), muscle strength, chest computed tomography (CT) and quality of life questionnaires. We evaluated factors correlating with recovery by linear mixed effects modelling.

Results:

Of 695 patients admitted, 299 and 226 returned at 3 and 12 months, respectively (median age 59 years, 69% male, 31% severe disease). About half and a third of the patients reported fatigue, dyspnoea and/or cognitive impairment at 3 and 12 months, respectively. Reduced 6MWD and quadriceps strength were present in 20% and 60% at 3 months versus 7% and 30% at 12 months. A high anxiety score and body mass index correlated with poor functional recovery. At 3 months, diffusing capacity for carbon monoxide (D LCO) and total lung capacity were below the lower limit of normal in 35% and 18%, decreasing to 21% and 16% at 12 months; predictors of poor D LCO recovery were female sex, pre-existing lung disease, smoking and disease severity. Chest CT improved over time; 10% presented non-progressive fibrotic changes at 1 year.

Conclusion:

Many COVID-19 survivors, especially those with severe disease, experienced limitations at 3 months. At 1 year, the majority showed improvement to almost complete recovery. To identify additional care or rehabilitation needs, we recommend a timely multidisciplinary follow-up visit following COVID-19 admission.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: 23120541.00004-2022

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: 23120541.00004-2022